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A B S T R A C T
Imatinib mesylate is a tyrosine kinase inhibitor with selectivity for abelson tyrosine-protein kinase 1
(c-Abl), breakpoint cluster region (Bcr)-Abl fusion protein (Bcr-Abl), mast/stem cell growth factor
receptor Kit (c-Kit), and platelet-derived growth factor receptor (PDGFR). Previous studies demonstrated
that imatinib in the low micromolar range exerted antiproliferative effects on neuroblastoma cell lines.
However, although neuroblastoma cells express c-Kit and PDGFR, the imatinib concentrations required
to achieve significant growth inhibitory effects (10 mM) are substantially higher than those required
for inhibition of ligand-induced phosphorylation of wild type c-Kit and PDGFR (1 mM), suggesting that
additional mechanisms are responsible for the antitumor activity of imatinib on these cells. In this study,
we show that treatment of neuroblastoma cell lines with 1–15 mM imatinib resulted in a dose dependent
inhibition of 5-bromo-20-deoxyuridine (BrdU) incorporation into newly synthesized DNA. The
antiproliferative effect of imatinib was dependent on the upregulation of the cyclin-dependent kinase
(CDK) inhibitor p27KIP1 in the nuclear compartment as a result of increased p27KIP1 protein stability.
We demonstrate that the mechanism of p27KIP1 stabilization relied on inhibition of p27KIP1
phosphorylation on tyrosine residues by c-Abl. We provide evidence that in neuroblastoma cell lines
a significant fraction of cellular c-Abl is phosphorylated on Tyr-245, consistent with an open and active
conformation. Notably, exposure to imatinib did not affect Tyr-245 phosphorylation. Given the low
affinity of active c-Abl for imatinib, these data provide a molecular explanation for the relatively high
imatinib concentrations required to inhibit neuroblastoma cell proliferation.
 2014 Elsevier Inc. All rights reserved.
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The CDK inhibitor p27KIP1 is a key regulator of G1 to S phase
transition in eukaryotic cells. In normal cells during G0 and early
G1 phase high levels of p27KIP1 bind to and inhibit the activity ofAbbreviations: CDK, cyclin-dependent kinase; c-Abl, abelson tyrosine-protein
kinase 1; Bcr-Abl, breakpoint cluster region (Bcr)-Abl fusion protein; c-Kit, mast/
stem cell growth factor receptor Kit; PDGFR, platelet-derived growth factor
receptor; SKP2, S-phase kinase-associated protein 2; HRP, horseradish peroxidase;
pRb, retinoblastoma protein; PARP, poly-(ADP-ribose)-polymerase; siRNA, short
interfering RNA; CHX, cycloheximide; BrdU, 5-bromo-20-deoxyuridine; df, degree
of freedom.
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0006-2952/ 2014 Elsevier Inc. All rights reserved.nuclear cyclin D-CDK4/6 and cyclin E-CDK2 complexes. During G1
to S phase transition, p27KIP1 abundance decreases, mainly because
of enhanced degradation, allowing the activation of cyclin-CDK
complexes to support S-phase entry [1,2]. The instability of p27KIP1
in late G1 is triggered by cyclin E-CDK2-dependent phosphory-
lation on Thr-187 which results in recruitment of p27KIP1 to a
S-phase kinase-associated protein 2 (SKP2)-containing ubiquitin
ligase and degradation by the 26S proteasome [3]. Reduced p27KIP1
protein levels caused by accelerated proteolysis characterize many
human cancers [1,2].
Previous studies have demonstrated that tyrosine phosphor-
ylation triggers the transition of p27KIP1 from inhibitor to non-
inhibitor of cyclin-CDK complexes and converts p27KIP1 into a
substrate of cyclin E-CDK2 complexes [4,5]. Of the three tyrosine
residues in p27KIP1 (Tyr-74, Tyr-88, and Tyr-89), the two adjacent
residues Tyr-88 and Tyr-89 are part of the inhibitory 310 helix of
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competes with ATP binding [6]. Upon tyrosine phosphorylation by
Abl- or Src-family non-receptor tyrosine kinases, the inhibitory 310
helix is ejected from the ATP-binding site of CDK2, partially
restoring CDK2 activity. This event would allow cyclin E-CDK2 to
phosphorylate Thr-187 leading to p27KIP1 proteolytic degradation
and complete CDK2 activation [4,5]. c-Abl is a 130 kDa protein
localized to the plasma membrane, cytosol and nucleus. The
activity of c-Abl is tightly regulated. Inactive c-Abl is in a closed
auto-inhibited conformation that involves several intra-molecular
interactions. Upon phosphorylation by upstream signaling kinases
or auto-phosphorylation events, c-Abl undergoes conformational
changes resulting in extensive domain rearrangements and
increased catalytic activity [7,8]. Tyr-412 and Tyr-245 are major
sites of regulatory control in c-Abl. Phosphorylation on Tyr-245, by
disrupting the intra-molecular engagement between the Src
homology (SH)3 domain and the SH2-kinase linker domain of
the auto-inhibited structure, stabilizes c-Abl in an open and active
conformation [9]. The small molecule inhibitor imatinib (STI-571)
specifically recognizes the inactive conformation of c-Abl. By
binding with high affinity (IC50 0.2 mM) to the ATP-binding
pocket of non-phosphorylated c-Abl, imatinib prevents binding of
ATP to the kinase domain, resulting in c-Abl inactivation.
Transition into the active conformation greatly reduces the affinity
of c-Abl for imatinib (IC50 7 mM) [10,11].
Previous studies have demonstrated that imatinib, a tyrosine
kinase inhibitor with selectivity for c-Abl, Bcr-Abl, c-Kit and PDGFR
[12], exerts antiproliferative effects on neuroblastoma cell lines
[13,14]. Although neuroblastoma cell lines express c-Kit and
PDGFR, the imatinib concentrations required to achieve significant
growth inhibitory effects (10 mM) are substantially higher than
those required for inhibition of ligand-induced phosphorylation of
wild type c-Kit and PDGFR (1 mM), suggesting that additional
mechanisms are responsible for the antitumor activity of imatinib
on these cells. In the present study the effects of imatinib on the
expression of the CDK inhibitor p27KIP1 were investigated in a
panel of neuroblastoma cell lines.
2. Materials and methods
2.1. Cell culture and drug treatments
The N-myc proto-oncogene protein (MYCN) amplified IMR5
[15] and MYCN single copy SJ-N-KP [16], SK-N-AS [17], and SK-N-
F1 [17] cell lines were used throughout this study. IMR5, SK-N-AS,
and SK-N-F1 cells have the wild-type and unamplified ALK gene
[18,19]. IMR5 and SK-N-F1 are of N-type [20,21], SK-N-AS cells are
of S-type [22]. IMR5, SK-N-AS, and SK-N-F1 cell lines were obtained
in October 2012 from Banca Biologica e Cell Factory, IRCCS Azienda
Ospedaliera Universitaria San Martino–IST Istituto Nazionale per la
Ricerca sul Cancro (Genova, Italy). The SJ-N-KP cell line was a kind
gift of Prof. Pession (Policlinico S. Orsola–Malpighi, Bologna, Italy)
and was received from his laboratory in October 2012. Cells were
passaged every 2–3 days and discarded after 8–10 passages. Cells
were maintained in monolayer cultures at 37 8C in a 5% CO2
humidified atmosphere. IMR5 and SJ-N-KP cells were cultured in
Roswell Park Memorial Institute (RPMI-1640 medium) (R-8758,
Sigma, Milan, Italy) whereas SK-N-AS and SK-N-F1 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (D-5796,
Sigma, Milan, Italy). RPMI-1640 and DMEM were supplemented
with 10% (v/v) fetal bovine serum (F-7524, Sigma, Milan, Italy) and
1% (v/v) antibiotic-antimycotic solution (A-5955, Sigma, Milan,
Italy) (complete medium). Imatinib mesylate (ALX-270-492) was
from Alexis (Florence, Italy) and was solubilized in DMSO (drug
vehicle, 41639 Fluka, Milan, Italy) at a final concentration of
10 mM, which was used as the stock solution for all experiments.Final dilutions were made in culture medium. Exponentially
growing neuroblastoma cells (2  106) cultured in complete
medium in 6-well plates were exposed to imatinib at the indicated
concentrations for 24 h (SJ-N-KP, IMR5, SK-N-F1) or 48 h (SK-N-
AS). For cycloheximide chase analysis neuroblastoma cells
(2  106) cultured in complete medium in 6-well plates were
exposed to 15 mM imatinib for 24 or 48 h, washed with fresh
culture medium and then treated with 25 mg/mL cycloheximide
(CHX) (C-4859, Sigma, Milan, Italy) added with DMSO or 15 mM
imatinib for further 4 or 8 h [23]. Whole cell extracts were
prepared at 0, 4 and 8 h and subjected to immunoblotting.
2.2. BrdU incorporation assays
The effects of imatinib on cell proliferation were tested using
5-bromo-20-deoxyuridine (BrdU) incorporation assay
(11669915001, Roche, Milan, Italy). Briefly, neuroblastoma cells
(2  104/well) were plated in 96 well culture plates and cultured in
complete medium. Increasing concentrations of imatinib were
added for 24 h (SJ-N-KP, IMR5, SK-N-F1) or 48 h (SK-N-AS). BrdU
label was added at a final concentration of 10 mM for the last 16 h.
Cells were treated with fixative/denaturing solution and then
incubated with anti-BrdU-peroxidase conjugate. BrdU incorpo-
ration was quantified according to the manufacturer’s instructions
using a GloMax luminometer (Promega, Milan, Italy). To evaluate
the effects of p27KIP1 gene silencing or expression of p27Y88F/Y89F or
wild type (WT) p27KIP1 on BrdU incorporation, cells transfected
with p27KIP1-targeting siRNA or a plasmid coding for p27Y88F/Y89F
or WT p27KIP1 were seeded into a 96-well culture plate (2  104
cells/well) and cultured for 24 h in complete medium before
addition of BrdU label at a final concentration of 10 mM for 16 h.
BrdU incorporation was quantified as described above.
2.3. Protein extraction, immunoblotting and immunoprecipitation
Polyclonal antibodies to p27KIP1 (sc-528), CDK4 (sc-260), CDK6
(sc-177), poly-(ADP-ribose)-polymerase (PARP) (sc-7150), cyclin E
(sc-481), cyclin D1 (sc-753), monoclonal antibodies to CDK2 (sc-
6248), cyclin A (sc-56300), pan-phosphotyrosine (sc-7020), and
horseradish peroxidise (HRP)-conjugated secondary antibodies
were from Santa Cruz Biotechnology (Heidelberg, Germany).
Polyclonal antibodies to c-Abl (2862), phospho-c-Abl tyrosine
(Tyr)-245 (2868) and phospho-pRb serine (Ser)-780 (3590) were
from Cell Signaling (Rome, Italy). Polyclonal antibody to phospho-
pRb threonine (Thr)-821 (9307) was from Biomol (Rome, Italy).
Monoclonal antibody to b-actin (A-5441) was from Sigma (Milan,
Italy). Monoclonal antibody to SKP2 (32-3300) and polyclonal
antibody to phospho-p27KIP1 Thr-187 (71-7700) were from Life
Technologies (Milan, Italy). IMR5, SJ-N-KP, SK-N-AS, and SK-N-F1
cells were collected using a cell scraper, washed with PBS, counted
manually, lysed with cell extraction buffer (FNN0011, Life
Technologies, Milan, Italy) (30 mL/1  106 cells) supplemented
with 1% (v/v) protease inhibitor mixture (P8340, Sigma, Milan,
Italy) and 4% (v/v) phosphatase inhibitor mixture (P-0044, Sigma,
Milan, Italy) and centrifuged at 15,000  g for 20 min at 4 8C.
Proteins were quantified using Protein Assay Kit II (500-0002, Bio-
Rad, Milan, Italy). Proteins (20 mg/lane) were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) on 9 or 12% gels and
electro-transferred (16 v, 12 h) at 4 8C to polyvinylidene fluoride
membranes (PVDF) (IPVH00010, Millipore, Milan, Italy) equili-
brated in Towbin buffer [24]. Membranes were blocked in 5% (w/v)
BSA (sc-2323, Santa Cruz Biotechnology, Heidelberg, Germany) in
20 mM Tris pH 7.6, 140 mM NaCl, 0.02% (v/v) Tween-20 (blocking
buffer) and probed with the indicated primary antibodies diluted
in blocking buffer. The commercial antibodies were used at
dilutions of 1:500–1:1000, except for the anti-b-actin antibody
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were incubated with HRP-conjugated secondary antibodies dilut-
ed in blocking buffer. Immunoreactive bands were revealed by
enhanced chemiluminscence (ECL) (Millipore, Milan, Italy) and
visualized using G:Box Chemi-XT CCD gel-imaging system and
GeneSnap image acquisition software (SynGene, Cambridge, UK).
Immunoreactive bands were quantitated using GeneTool softwareFig. 1. Imatinib inhibits BrdU incorporation and promotes the upregulation of p27KIP1
Neuroblastoma cells were incubated for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N-AS) in
Evaluation of BrdU incorporation. Values are means  SD of three independent experiments
controls: 1.9  106 (IMR5), 1.5  106 (SJ-N-KP), 2.1  106 (SK-N-AS), 2.9  106 (SK-N-F1). (B
relative band intensity quantified by densitometric analysis and normalized using b-actin ba
Values are means  SD of five independent experiments. One representative immunoblot is s
were stained with anti p27KIP1 antibody (red). Nuclei were stained with Hoechst-33258 (blu
independent experiments are shown. Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 ((SynGene, Cambridge, UK). Immunoprecipitation of p27KIP1 or c-
Abl from whole cell extracts were carried-out using the indicated
antibodies conjugated to Dynabeads protein-A (100.01D, Life
Technologies, Milan, Italy) according to manufacturer’s specifica-
tions. Dynabeads-IgG conjugates were combined with 100 mL
whole cell extract containing 500 mg protein (DMSO treated cells
or cells transfected with non-targeting control siRNA or emptyin the nuclear compartment.
 the absence (DMSO) or presence of imatinib (Im) at the indicated concentrations. (A)
 and are expressed as percent of DMSO (control). Absolute chemiluminescence values of
) Immunoblotting analysis using anti-p27KIP1 antibody. Histograms represent p27KIP1
nds as reference. Band intensity in cells exposed to 15 mM imatinib is set to 1 (control).
hown. (C) Immunofluorescence microscopy analysis. Permeabilized neuroblastoma cells
e). Merged color images are shown in the last column. Representative results of three
versus DMSO), df = 4; #P < 0.05, ##P < 0.01, ###P < 0.001 (versus 15 mM imatinib), df = 8.
Fig. 2. Knockdown of p27KIP1 impairs the antiproliferative effect of imatinib.
Neuroblastoma cells were transfected with p27KIP1-targeting siRNAs or non-
targeting control siRNA (scramble). After 24 h from transfection, cells were treated
with 15 mM imatinib for additional 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N-
AS). (A) Evaluation of p27KIP1 expression by immunoblot analysis. Histograms
represent p27KIP1 relative band intensity quantified by densitometric analysis and
normalized using b-actin bands as reference. Band intensity in scramble exposed to
15 mM imatinib is set to 1 (control). Values are means  SD of three independent
experiments. One representative immunoblot is shown. (B) Evaluation of BrdU
incorporation. Values are means  SD of three independent experiments and are
expressed as percent of BrdU incorporation in cells transfected with scramble and
exposed to DMSO (control). Absolute chemiluminescence values of controls: 1.2  106
(IMR5), 1.1  106 (SJ-N-KP), 1.2  106 (SK-N-AS), 1.2  106 (SK-N-F1). Statistical
significance: ##P < 0.01, ###P < 0.001 (versus scramble + 15 mM imatinib), df = 4;
***P < 0.001 (versus scramble + DMSO), df = 4.
Comparable results were obtained when cells were transfected with a pool of two
p27KIP1-targeting siRNAs or when each siRNA was used individually.
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transfected with siRNAs or plasmid DNA) and incubated with
rotation for 1 h at 4 8C. Supernatant was removed, beads were
washed twice with 500 mL PBS containing 0.02% (v/v) Tween-20,
and proteins were eluted with 30 mL 0.1 M citrate pH 3.1. Fol-
lowing neutralization with 20 mL 1 M Tris pH 9, eluted proteins
were mixed 1:1 with Laemmli sample buffer and subjected
to immunoblot analysis. To verify the specificity of phospho-c-
Abl Tyr-245 antibody, c-Abl immunoprecipitates were treated
for 2 h at 37 8C with 10 U alkaline phosphatase (AP+) (P-4252,
Sigma, Milan, Italy) or vehicle (AP), mixed 1:1 with Laemmli
sample buffer, heated at 95 8C for 5 min, before immunoblot
analysis.
2.4. Immunofluorescence microscopy
Cells (1  105) were fixed in 4% (w/v) paraformaldehyde in
PBS for 30 min, washed with PBS, permeabilized with PBS
containing 0.1% (v/v) Triton X-100 and 15 mM NaN3 (PBS-Triton
buffer), and blocked in PBS-Triton buffer containing 2% (w/v) BSA
for 1 h. Cells were incubated overnight at 48C with the primary
antibody (sc-528) diluted 1:500 in PBS-Triton buffer, washed
with PBS-Triton buffer, and incubated for 1 h with Cy3-
conjugated goat anti-rabbit secondary antibody (AP132C, Milli-
pore, Milan, Italy) diluted 1:1000 in PBS-Triton buffer. Nuclei
were stained for 20 min in the dark with Hoechst-33258
(861405, Sigma, Milan, Italy) to a final concentration of
500 ng/mL. Images were acquired using a Leica DMI 4000 B
inverted microscope (Milan. Italy).
2.5. RNA interference
siRNAs targeting the human forms of CDK2 or p27KIP1 or c-Abl
and control nontargeting siRNA (1027280, AllStar negative
control) were purchased from Qiagen, Milan, Italy. Two CDK2
targeting siRNAs (SI00299775; SI02654638), two p27KIP1 targeting
siRNAs (SI02621990; SI02621997) and four c-Abl targeting siRNAs
(SI00288316; SI00288323; SI00299082; SI00299089) were tested
individually. Neuroblastoma cells (2  106) were transfected in a
volume of 100 mL with 3 pmol siRNA using Amaxa Nucleofector
device (Lonza, Rome, Italy). Nucleofector kit V and program C-005
were used for IMR5 and SJ-N-KP cells; nucleofector kit V and
program X-005 were used for SK-N-F1 cells; nucleofector kit T and
program B-013 were used for SK-N-AS cells. Following transfec-
tion, cells were cultured for 24 h before further treatments or
expression analysis.
2.6. Real-time PCR
Total RNA was extracted from 2  106 cells, and converted to
cDNA as previously described [24]. Primers were designed using
Primer3 (http://frodo.wi.mit.edu) and synthesized by MWG
(Martinsried, Germany). SKP2 mRNA (NM_005983.3) was ampli-
fied from 749 to 962 with primers forward 50-catttcagcccttttcgtgt-
30 and reverse 50-gggcaaattcagagaatcca-30. CCNA2 (cyclin A) mRNA
(NM_001237.3) was amplified from 1366 to 1587 with primers
forward 50-ttattgctggagctgccttt-30 and reverse 50-ctggtgggttgagga-
gagaa-30. CDKN1B (p27KIP1) (NM_004064.3) was amplified from
836 to 1008 with primers forward 50-ccggctaactctgaggacac-30 and
reverse 50-ggggaaccgtctgaaacatt-30. ACTB (beta cytoskeletal actin)
mRNA (NM_001101.3) was amplified from 698 to 969 with
primers forward 50-agcgggaaatcgtgcgtgacatta-30 and reverse 50-
ggcgtacaggtctttgcggatgtc-30. Relative transcript abundance was
calculated by CFX Manager software (Bio-Rad, Milan, Italy) using
the DDCt method with ACTB as the reference gene. All samples
were assayed in triplicate.2.7. Cloning and site-directed mutagenesis
Plasmids encoding human full-length pRb (IMAGE ID:
5267622) and p27KIP1 (IMAGE ID: 3458141) were obtained from
Source Bioscience (Nottingham, UK) and purified from bacterial
cultures using a Plasmid Midi Kit (12143, Qiagen, Milan, Italy). The
human p27KIP1 coding sequence was amplified using Pfu
thermostable DNA polymerase (600670-51, Agilent, Milan, Italy)
in the presence of the forward primer 50-caccatgtcaaacgtgcgagtgtc-
taac-30, in which the 50-cacc-30 sequence comprising the topo-
isomerase I recognition site was fused to the sequence
corresponding to positions 473–496 of human p27KIP1 mRNA
(NM_004064.3), and the reverse primer 50-ttacgtttgacgtcttctgaggc-
cag-30 corresponding to positions 1044–1069. A sequence coding
for a truncated form of human pRb (pRbD882) comprising amino
acids 373–882 was amplified using Pfu thermostable DNA
polymerase in the presence of the forward primer 50-caccatgactc-
cagttaggactgttatg-30, in which the 50-cacc-3’ sequence was fused to
the sequence corresponding to positions 1283–1303 of human pRb
mRNA (NM_000321.2), and the reverse primer 50-tcatgatccttcaa-
tatcaaagcgtagtt-30 corresponding to positions 2787–2812. The
amplification products were gel-purified using the Qiaquick Gel
Extraction Kit (28704, Qiagen, Milan, Italy), subcloned into
pcDNA3.1 directional TOPO expression vector (K4900-01, Life
Technologies, Milan, Italy), and transformed into Top 10 chemically
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transformants, plasmids were purified from bacterial cultures
using EndoFree Plasmid Kit (12362, Qiagen, Milan, Italy) and
sequenced at MWG. The purified plasmids were dissolved in sterile
TE buffer (10 mM Tris pH 7.6, 1 mM EDTA). Plasmid coding for a
mutant nonphosphorylatable form of p27KIP1 (p27 Y88F/Y89F) was
obtained using QuikChange Multi Site-Directed Mutagenesis Kit
(200514, Agilent, Milan, Italy) in the presence of the primer 50-
agcttgcccgagttcttcttcagacccccgc-30. Automated sequencing con-
firmed that the expected mutations were introduced into theFig. 3. Imatinib promotes p27KIP1 upregulation as a result of p27KIP1 protein stabilizati
(A) Neuroblastoma cells were incubated for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N
levels evaluated by real-time PCR. Results are expressed as arbitrary units. p27KIP1 expres
independent experiments. (B) Neuroblastoma cells were exposed to 15 mM imatinib as
CHX + 15 mM imatinib and further incubated for the indicated times. Whole cell extracts w
Histograms represent p27KIP1 relative band intensity quantified by densitometric analysis an
to 1 (control). Values are means  SD of three independent experiments. One representativ
cells), df = 4; *P < 0.05, **P < 0.01, ***P < 0.001 (versus time 0), df = 4.sequence. For recombinant protein expression, neuroblastoma
cells (2  106) were transfected with 3 mg of the indicated plasmid
or empty vector using Amaxa Nucleofector as described in section
2.5.
2.8. Caspase 3/7 activity assay
Cells (2  104/well) were seeded in 100 mL complete medium
into a black 96 well culture plate, treated with 15 mM imatinib
or drug vehicle (DMSO) for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 hon.
-AS) in the absence (DMSO) or presence of 15 mM imatinib (Im) and p27KIP1 mRNA
sion in DMSO-treated IMR5 cells is set to 1 (control). Values are means  SD of three
 described in (A), washed with fresh culture medium, added with CHX + DMSO or
ere prepared and analyzed by immunoblot analysis using a p27KIP1 specific antibody.
d normalized using b-actin bands as reference. The intensity of the bands at time 0 is set
e immunoblot is shown. Statistical significance: ##P < 0.01, ###P < 0.001 (versus IMR5
E. Lupino et al. / Biochemical Pharmacology 92 (2014) 235–250240(SK-N-AS) and cultured at 37 8C for 24 h in a 5% CO2 humidified
atmosphere. As positive control, cells were treated with 20 nM
epoxomicin (EPX) (sc-201298, SantaCruz, Heidelberg, Germany)
for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N-AS) [25]. At the
end of incubation 100 mL of Apo-ONE Homogeneous Caspase-3/7
Reagent (Promega, Milan, Italy) was added in each well. The plate
was mixed for 5 min on a plate shaker at 300–500 rpm and
incubate at room temperature for 10 h. Fluorescence wasFig. 4. Effects of imatinib on p27KIP1 phosphorylation on tyrosine residues and Thr-187
Neuroblastoma cells were incubated for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N-AS)
(A) Evaluation of p27KIP1 phosphorylation. p27KIP1 was immunoprecipitated with anti-
phosphorylation status. Whole cell extracts were analyzed by immunoblot analysis us
relative band intensity of the indicated proteins quantified by densitometric analysis an
DMSO-treated cells is set to 1 (control). Values are means  SD of three independent exp
**P < 0.01, ***P < 0.001 (versus DMSO), df = 4.measured in each well at 485 nm (excitation) and 530 nm
(emission) using a Fluoroskan Ascent-Thermo microplate fluo-
rometer (Thermo-Fisher Scientific, Milan, Italy).
2.9. Statistical analysis
Student’s t-test was used for statistical comparison of
differences. P < 0.05 was considered significant..
 in the absence (DMSO) or presence of imatinib (Im) at the indicated concentrations.
p27KIP1 antibody and blotted with the indicated antibodies. (B) Evaluation of pRb
ing anti phospho-pRb Thr-821 antibody. Histograms in panels A and B represent
d normalized using p27KIP1 (A) or b-actin (B) bands as reference. Band intensity in
eriments. One representative immunoblot is shown. Statistical significance: *P < 0.05,
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3.1. Imatinib inhibits BrdU incorporation and promotes the
upregulation of p27KIP1 in the nuclear compartment
Exposure of IMR5, SJ-N-KP, SK-N-F1 and SK-N-AS neuroblasto-
ma cell lines to 1–15 mM imatinib, resulted in a dose dependent
inhibition of BrdU incorporation into newly synthesized DNA
(Fig. 1A). A 24 h period of drug exposure was used for IMR5, SJ-N-
KP and SK-N-F1 cells. At variance, exposure of SK-N-AS cells to
imatinib was prolonged to 48 h to reach an inhibitory effectFig. 5. CDK2 knockdown reveals constitutive phosphorylation of p27KIP1 on tyrosine re
Neuroblastoma cells were transfected with CDK2-targeting siRNAs or non-targeting cont
anti-CDK2 or anti-p27KIP1 specific antibodies. (B) Immunoprecipitation with anti-p27KIP
represent relative band intensity of the indicated proteins quantified by densitometric 
intensity in scramble is set to 1 (control). Values are means  SD of three independent expe
(versus scramble), df = 4.
Comparable results were obtained when cells were transfected with a pool of two CDK2-comparable with that of the other three cell lines. No activation of
caspase-3/7 or PARP degradation was detected in imatinib treated
cells (not shown), thus excluding apoptosis as the cause of reduced
BrdU incorporation. Taken together, these results suggest an
impairment in G1 to S phase transition. No changes in the
expression of cyclin E and CDK2 or cyclin D1 and CDK4/6 which
regulate S phase entry [26] were revealed in imatinib treated cells
(not shown). At variance, a dose dependent increase in the
expression of the CDK inhibitor p27KIP1 was detected (Fig. 1B).
Fluorescence microscopy analysis provided evidence of nuclear
localization of p27KIP1 in imatinib treated cells (Fig. 1C). To furthersidues.
rol siRNA (scramble) and cultured for additional 24 h. (A) Immunoblot analysis with
1 antibody followed by immunoblotting with the indicated antibodies. Histograms
analysis and normalized using b-actin (A) or p27KIP1 (B) bands as reference. Band
riments. One representative immunoblot is shown. Statistical significance: ***P < 0.001
targeting siRNAs or when each siRNA was used individually.
Fig. 6. Effects of c-Abl knockdown on p27KIP1 expression and phosphorylation status.
Neuroblastoma cells were transfected with c-Abl-targeting siRNAs or non-targeting control siRNA (scramble) and cultured for additional 24 h. (A) Immunoblot analysis with
anti-c-Abl or anti-p27KIP1 antibodies. Histograms represent c-Abl and p27KIP1 relative band intensity quantified by densitometric analysis and normalized using the b-actin
bands as reference. Band intensity in scramble is set to 1 (control). Values are means  SD of five independent experiments. (B) Real-time PCR evaluation of p27KIP1mRNA levels.
Results are expressed as arbitrary units. Expression in IMR5 cells transfected with scramble siRNA is set to 1 (control). Values are means  SD of three independent experiments. (C)
Immunoprecipitation with anti-p27KIP1 antibody followed by immunoblotting with the indicated antibodies. Equal protein loading was verified by stripping and reprobing each blot
with an antibody to p27KIP1. One representative immunoblot of three independent experiments is shown. (D) Evaluation of the interaction between p27KIP1 and c-Abl. p27KIP1 was
immunoprecipitated with anti-p27KIP1 antibody as in Fig. 4A and blotted with anti c-Abl antibody. Histogram represents c-Abl relative band intensity quantified by densitometric
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imatinib on p27KIP1, the expression of p27KIP1 was downregulated
by siRNA-mediated gene silencing (Fig. 2A). Noteworthy, in
neuroblastoma cells depleted of p27KIP1 the inhibitory effect of
15 mM imatinib on BrdU incorporation did not reach statistical
significance, thus excluding a direct inhibitory effect of imatinib on
BrdU incorporation (Fig. 2B). To determine the mechanism of
p27KIP1 upregulation, mRNA expression and protein stability were
investigated. In all cell lines, no significant changes in p27KIP1
mRNA levels were detected by real-time PCR assays between
DMSO and imatinib treated cells (Fig. 3A). In contrast, cyclohexi-
mide chase analysis evidenced an increased p27KIP1 protein
stability in cells exposed to imatinib (Fig. 3B). Taken together,
these results support the conclusion that the antiproliferative
effect of imatinib on neuroblastoma cells relies on p27KIP1
upregulation in the nuclear compartment caused by increased
p27KIP1 protein stability.
3.2. Exposure to imatinib decreases p27KIP1 phosphorylation on Thr-
187 and tyrosine residues
Cyclin E-CDK2-dependent phosphorylation at Thr-187 plays a
well established role in the regulation of p27KIP1 protein stability
[27]. Moreover, recent results suggest that p27KIP1 phosphoryla-
tion on Thr-187 is primed by phosphorylation on tyrosine residues
by non-receptor tyrosine kinases [4]. To study this, p27KIP1 was
immunoprecipitated from neuroblastoma cells exposed to 10 or
15 mM imatinib or drug vehicle and blotted using anti phospho-
p27KIP1 Thr-187 or anti phospho-tyrosine specific antibodies. As
shown in Fig. 4A, a dose dependent decrease in p27KIP1 phospho-
Thr-187 and phospho-tyrosine content was detected in cells
exposed to imatinib. Moreover, in agreement with the notion that
binding of p27KIP1 to cyclin-CDK2 is inversely related to p27KIP1
tyrosine phosphorylation [28], a dose dependent increase in the
amount of CDK2 was observed in p27KIP1 immunoprecipitates
from imatinib treated cells. Collectively, these results are consis-
tent with a model in which imatinib by inhibiting p27KIP1
phosphorylation on tyrosine residues restores p27KIP1 inhibitory
activity on CDK2, resulting in decreased Thr-187 phosphorylation.
In agreement with this hypothesis, in neuroblastoma cells exposed
to imatinib, the phosphorylation of pRb at the CDK2 specific Thr-
821 [29] was consistently reduced (Fig. 4B).
3.3. In neuroblastoma cells p27KIP1 is constitutively phosphorylated
on tyrosine residues
To investigate the mechanism of p27KIP1 tyrosine phosphory-
lation, neuroblastoma cells were transfected with CDK2-targeting
siRNAs, in order to suppress Thr-187 phosphorylation. As shown in
Fig. 5A, depletion of CDK2 resulted in the upregulation p27KIP1
which contained a greatly decreased amount of phosphorylated
Thr-187 but unchanged levels of phosphotyrosine (Fig. 5B). Taken
together, these results are consistent with the conclusion that in
neuroblastoma cells p27KIP1 is constitutively phosphorylated on
tyrosine residues and indicate that p27KIP1 tyrosine phosphory-
lation is independent of Thr-187 phosphorylation.
3.4. Silencing of c-Abl recapitulates the effects of imatinib on p27KIP1
expression levels
To investigate the potential involvement of c-Abl in p27KIP1
tyrosine phosphorylation, neuroblastoma cells were transfectedanalysis and normalized using p27KIP1 bands as reference. Band intensity in IMR5 cells is set
***P < 0.001 (versus scramble), df = 8; §§P < 0.01, §§§P < 0.001 (versus IMR5 cells transfecte
Comparable results were obtained when cells were transfected with a pool of four c-Abl-twith c-Abl-targeting siRNAs. As shown in Fig. 6A and B, depletion
of c-Abl resulted in the upregulation of p27KIP1 in the absence of
significant changes in p27KIP1 mRNA levels. Importantly, in p27KIP1
immunoprecipitates virtually no phosphotyrosine or phospho-
Thr-187 was detected, recapitulating the effects of imatinib
(Fig. 6C). Taken together, these results highlight a so far unknown
role for c-Abl in the regulation of p27KIP1 tyrosine phosphorylation
in vivo and are consistent with the notion that phosphorylation on
tyrosine residues primes p27KIP1 for Thr-187 phosphorylation. In
addition, these data support the conclusion that in neuroblastoma
cells exposed to imatinib p27KIP1 stabilization results from
inhibition of c-Abl-dependent phosphorylation on tyrosine resi-
dues. Of note, analysis of p27KIP1 immunoprecipitates from
untransfected DMSO-treated neuroblastoma cells with anti c-
Abl antibody, evidenced significant amounts of c-Abl, indicating a
direct interaction between p27KIP1 and c-Abl (Fig. 6D).
3.5. Expression of p27Y88F/Y89F but not wild type p27KIP1 recapitulates
the effects of imatinib on BrdU incorporation
Tyr-88 and Tyr-89 are major phospho-acceptor sites of p27KIP1
targeted by c-Abl [4,5]. To further test the effects of the loss of
p27KIP1 phosphorylation on tyrosine residues, neuroblastoma cells
were transfected with a plasmid coding for a mutant form of
p27KIP1 (p27Y88F/Y89F) which cannot be phosphorylated on Tyr-88
and Tyr-89 or wild type p27KIP1. Transfection with p27Y88F/Y89F but
not wild type p27KIP1, resulted in the expression of a stable protein
(Fig. 7A) which was devoid of phosphorylated Thr-187 (Fig. 7B) and
recapitulated the effects of imatinib on BrdU incorporation
(Fig. 7C). In addition, expression of p27Y88F/Y89F recapitulated
the effects of imatinib on pRb phosphorylation at Thr-821 (Fig. 7D).
These data support the conclusion that in neuroblastoma cells
tyrosine phosphorylation negatively regulates p27KIP1 stability and
p27KIP1 inhibitory activity on CDK2 and that suppression of p27KIP1
phosphorylation on tyrosine residues exerts growth inhibitory
effects on neuroblastoma cells.
3.6. In neuroblastoma cells c-Abl is constitutively phosphorylated on
Tyr-245
To investigate c-Abl activation status, c-Abl was immunopre-
cipitated from cell extracts of exponentially growing neuroblasto-
ma cells and immunoblotted using an antibody to phospho-c-Abl
Tyr-245. As shown in Fig. 8A and B, Tyr-245 phosphorylated c-Abl
was detected in all cell lines, suggesting that a significant fraction
of cellular c-Abl is in an open and active conformation. The highest
level of Tyr-245 phosphorylated c-Abl was detected in SK-N-AS
cells. Exposure to imatinib did not affect c-Abl phosphorylation on
Tyr-245 in any of the cell lines examined (Fig. 8C).
3.7. Exposure to imatinib downregulates the expression of SKP2 and
cyclin A
Loss of phosphorylation on tyrosine residues converts p27KIP1
from a bound non-inhibitor to a bound inhibitor of cyclin D-CDK4
complexes [5]. To evaluate the effects of imatinib on CDK4 activity,
the phosphorylation status of pRb at the CDK4-specific Ser-780
[30] was investigated. As shown in Fig. 9A, in cells exposed to
10 and 15 mM imatinib phosphorylation of Ser-780 was reduced,
suggesting a decreased CDK4 activity. Collectively, the above
reported results indicate that in imatinib treated cells pRb
phosphorylation at CDK2- and CDK4-specific sites is reduced. to 1. Values are means  SD of three independent experiments. Statistical significance:
d with scramble siRNA), df = 4; #P < 0.05, ##P < 0.01 (versus IMR5 cells), df = 4.
argeting siRNAs or when each siRNA was used individually.
Fig. 7. Effects of the expression of p27Y88F/Y89F.
Neuroblastoma cells were transfected with a plasmid coding for p27Y88F/Y89F or wild type (WT) p27KIP1 or empty plasmid (vector) and cultured for additional 24 h. (A)
Immunoblot analysis using anti p27KIP1 antibody. (B) Immunoprecipitation with anti-p27KIP1 antibody followed by immunoblotting with anti phospho-p27KIP1 Thr-187
antibody. Equal protein loading was verified by stripping and reprobing each blot with an antibody to p27KIP1. One representative immunoblot of three independent
experiments is shown. (C) Evaluation of BrdU incorporation. Values are means  SD of three independent experiments and are expressed as percent of BrdU incorporation in cells
transfected with vector and exposed to DMSO (control). Absolute chemiluminescence values of controls: 4.7  106 (IMR5), 2.4  106 (SJ-N-KP), 1.6  106 (SK-N-AS), 1.7  106 (SK-
N-F1). (D) Immunoblot analysis using anti phospho-pRb Thr-821 antibody. Histograms in panels A and D represent p27KIP1 (A) and phospho-pRb Thr-821 (D) band intensity
quantified by densitometric analysis and normalized using b-actin bands as reference. Band intensity in vector is set to 1 (control). Values are means  SD of three independent
experiments. One representative immunoblot is shown. Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 (versus vector), df = 4; ###P < 0.001 (versus vector + DMSO), df = 4.
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Fig. 8. Evaluation of c-Abl phosphorylation on Tyr-245.
(A) c-Abl was immunoprecipitated from whole cell extracts using anti c-Abl antibody and immunoblotted with anti phospho-c-Abl Tyr-245 antibody. (B) Specificity of anti
phospho-c-Abl Tyr-245 antibody. c-Abl immunoprecipitates were treated (AP+) or not (AP) with alkaline phosphatase followed by immunoblotting with anti phospho-c-
Abl Tyr-245 antibody. (C) Effects of imatinib on c-Abl phosphorylation. Neuroblastoma cells were exposed for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N-AS) to 15 mM
imatinib or DMSO and c-Abl phosphorylation at Tyr-245 evaluated as described in (A). Histograms in panels A–C represent phospho-c-Abl Tyr-245 band intensity quantified
by densitometric analysis and normalized using c-Abl bands as reference. In histogram A, band intensity in IMR5 cells is set to 1. In histogram B, band intensity in AP is set to
1 (control). In histogram C, band intensity in DMSO treated cells is set to 1 (control). Values are means  SD of three independent experiments. One representative immunoblot is
shown. Statistical significance: *P < 0.05, **P < 0.01 (versus IMR5 cells) df = 4; ###P < 0.001 (versus AP) df = 4.
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Fig. 9. Effects of imatinib on pRb phosphorylation and SKP2 and cyclin A expression.
Neuroblastoma cells were incubated for 24 h (IMR5, SJ-N-KP, SK-N-F1) or 48 h (SK-N-AS) in the absence (DMSO) or presence of imatinib (Im) at the indicated concentrations.
(A) Immunoblot analysis using anti phospho-pRb Ser-780 antibody. (B and C) Evaluation of SKP2 and cyclin A mRNA and protein expression by real-time PCR (B) and
immunoblot analysis (C). Histograms in panels A and C represent phospho-pRb Ser-780 (A) and SKP2 and cyclin A (C) band intensity quantified by densitometric analysis and
normalized using b-actin bands as reference. Band intensity in DMSO treated cells is set to 1 (control). Values are means  SD of three independent experiments. One
representative immunoblot is shown. Histograms in panel B represent relative SKP2 and cyclin A mRNA levels. Results are expressed as arbitrary units. Expression in DMSO-treated
cells is set to 1 (control). Values are means  SD of three independent experiments. Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 (versus DMSO treated cells) df = 4.
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Fig. 10. Effects of silencing of p27KIP1 or expression of p27Y88F/Y89F on E2F target
genes.
(A and B) Cells were transfected with p27KIP1-targeting siRNAs or with non-
targeting control siRNA (scramble). After 24 h from transfection, cells were treated
with 15 mM imatinib for additional 24 h (SJ-N-KP, IMR5, SK-N-F1) or 48 h (SK-N-AS)
and SKP2 and cyclin A mRNA and protein expression evaluated by real-time PCR (A)
and immunoblot analysis (B). Histograms in panel A represent SKP2 and cyclin A
relative mRNA levels. Results are expressed as arbitrary units. Expression in
scramble is set to 1 (control). Values are means  SD of three independent
experiments. Histogram in panel B represents SKP2 and cyclin A band intensity
quantified by densitometric analysis and normalized using b-actin bands as reference.
Band intensity in scramble is set to 1 (control). Values are means  SD of three
independent experiments. One representative immunoblot is shown. (C and D) Cells
were transfected with a plasmid coding for p27Y88F/Y89F or empty plasmid (vector).
After 24 h from transfection, SKP2 and cyclin A mRNA and protein expression were
evaluated by real-time PCR (C) and immunoblot analysis (D). Histograms in panel C
represent SKP2 and cyclin A relative mRNA levels. Results are expressed as arbitrary
units. Expression in vector is set to 1 (control). Values are means  SD of three
independent experiments. Histogram in panel D represents SKP2 and cyclin A band
intensity quantified by densitometric analysis and normalized using b-actin bands as
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activity is decreased. To test this hypothesis, the expression of
SKP2 and cyclin A, two E2F responsive genes known to be
upregulated in neuroblastoma cells [30,31] was evaluated. As
shown in Fig. 9B and C, in cells exposed to 10 and 15 mM imatinib
the expression of SKP2 and cyclin A was decreased at the mRNA
and protein levels. Importantly, in cells subjected to p27KIP1 gene
silencing the effects of imatinib on the expression of SKP2 and
cyclin A were prevented, thus excluding a direct inhibitory effect
of imatinib on SKP2 and cyclin A expression (Fig. 10A and B).
Expression of p27Y88F/Y89F but not wild type p27KIP1 (not shown)
recapitulated the effects of imatinib on SKP2 and cyclin A
expression (Fig. 10C and D). Taken together, these data indicate
that p27KIP1-dependent downregulation of E2F-controlled cell
cycle regulatory genes is an important consequence of the
exposure of neuroblastoma cells to imatinib.
Of note, transfection of neuroblastoma cells with a plasmid
coding for a constitutively active form of pRb that lacks all cyclin D-
CDK docking sites and all but one potential cyclin E-CDK docking
sites (pRbD882) [32], caused the downregulation of SKP2 and
cyclin A expression, demonstrating that in neuroblastoma cells
SKP2 and cyclin A expression can be repressed by active pRb
(Fig. 11).
4. Discussion
In the present study we found that exposure of neuroblasto-
ma cell lines to 1-15 mM imatinib resulted in a dose dependent
inhibition of BrdU incorporation into newly synthesized DNA.
This effect was dependent on the upregulation of the CDK
inhibitor p27KIP1 in the nuclear compartment as demonstrated
by siRNA-mediated depletion of p27KIP1, which prevented the
effects of imatinib on BrdU incorporation. Regulation of p27KIP1
protein levels is mainly achieved by ubiquitin dependent
proteolysis [27,33]; however, increased p27KIP1 mRNA levels
in imatinib-treated cells have been described [34]. Real-time PCR
assays ruled-out increased p27KIP1 mRNA levels in neuroblasto-
ma cells exposed to imatinib. In contrast, cycloheximide chase
assays demonstrated a substantial increase in p27KIP1 protein
stability. Taken together, these results support the conclusion
that p27KIP1 upregulation in the nuclear compartment promoted
by increased protein stability mediates the antiproliferative
effects of imatinib on neuroblastoma cells. The lower p27KIP1
gene expression in MYCN-amplified IMR5 cells (Fig. 3A) provides
an explanation of the apparently less efficient stabilization of
p27KIP1 in this cell line (Fig. 3B). Phosphorylation at Thr-187 by
cyclin E-CDK2 plays a well established role in the regulation of
p27KIP1 protein stability [3]. In addition, phosphorylation on
tyrosine residues by Abl- or Src-family non-receptor tyrosine
kinases has been demonstrated to prime p27KIP1 for Thr-187
phosphorylation [4]. We provide evidence that in neuroblastoma
cells exposed to imatinib, the content of phospho-Thr-187 and
phospho-tyrosine in p27KIP1 immunoprecipitates consistently
decreased. This result supports a model in which imatinib by
inhibiting p27KIP1 tyrosine phosphorylation restores the inhibi-
tory activity of p27KIP1 itself on cyclin E-CDK2 resulting in
decreased phosphorylation at Thr-187. To test this hypothesis,reference. Band intensity in vector is set to 1 (control). Values are means  SD of three
independent experiments. One representative immunoblot is shown. Statistical
significance: **P < 0.01, ***P < 0.001 (versus scramble), df = 4; ##P < 0.01,
###P < 0.001 (versus vector), df = 4.
Comparable results were obtained when cells were transfected with a pool of two
p27KIP1-targeting siRNAs or when each siRNA was used individually.
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mediated gene silencing, which resulted in the upregulation
of endogenous p27KIP1 containing a greatly decreased amount
of phosphorylated Thr-187 but an unchanged phosphotyrosine
level. These results demonstrate that in proliferating neuroblas-
toma cells p27KIP1 is constitutively phosphorylated on tyrosine
residues and indicate that p27KIP1 phosphorylation on tyrosine
residues does not require prior phosphorylation at Thr-187.
Previous studies have demonstrated that overexpression of
c-Abl in eukaryotic cells promotes p27KIP1 phosphorylation on
tyrosine residues [35] therefore, the potential involvement of
c-Abl in p27KIP1 tyrosine phosphorylation in neuroblastoma cell
lines was investigated. To do this, neuroblastoma cells were
transfected with siRNAs to c-Abl. Depletion of c-Abl resulted in
the upregulation of p27KIP1 in the absence of changes in p27KIP1
mRNA levels. Strikingly, virtually no phosphotyrosine or
phosphorylated Thr-187 was detected in p27KIP1 immunopreci-
pitates from cells subjected to c-Abl knockdown, recapitulatingFig. 11. Effects of the expression of pRbD882.
Neuroblastoma cells were transfected with pRbD882 or empty plasmid (vector) and SK
immunoblot analysis (B). Histograms in panel A represent relative SKP2 and cyclin A m
(control). Values are means  SD of three independent experiments. Histogram in panel B
normalized using b-actin bands as reference. Band intensity in vector is set to 1 (control). Val
is shown. Statistical significance: ##P < 0.01, ###P < 0.001 (versus vector), df = 4.the effects of imatinib. Immunoprecipitation experiments
provided evidence of the interaction between c-Abl and
p27KIP1, consistent with a direct mechanism of phosphorylation
(Fig. 6D). Collectively, these results highlight a previously
unknown role for c-Abl in the regulation of p27KIP1 stability in
vivo and support the conclusion that inhibition of c-Abl-
dependent phosphorylation of p27KIP1 on tyrosine residues is
the mechanism of the imatinib-mediated stabilization of p27KIP1
in neuroblastoma cells. To further test the effects of the loss of
p27KIP1 phosphorylation on tyrosine residues, neuroblastoma
cells were transfected with a plasmid coding for a mutated form
of p27KIP1 (p27Y88F/Y89F) that cannot be phosphorylated on Tyr-
88 and Tyr-89, the major phospho-acceptor sites of p27KIP1
targeted by c-Abl [4,5]. Transfection with p27Y88F/Y89F but not
with a plasmid coding for wild type p27KIP1, resulted in the
expression of a stable protein which lacked phosphorylated
Thr-187. Moreover, expression of p27Y88F/Y89F but not wild
type p27KIP1, recapitulated the effects of imatinib on BrdUP2 and cyclin A mRNA and protein expression evaluated by real-time PCR (A) and
RNA levels. Results are expressed as arbitrary units. Expression in vector is set to 1
 represents SKP2 and cyclin A band intensity quantified by densitometric analysis and
ues are means  SD of three independent experiments. One representative immunoblot
Fig. 12. Model of the proposed mechanism of p27KIP1 inactivation in neuroblastoma
cells.
Active c-Abl phosphorylates p27KIP1 at tyrosine residues 88 and 89 resulting in
CDK2 partial activation. Following CDK2-dependent phosphorylation on Thr-187,
p27KIP1 is degraded by the 26S proteasome and full CDK2 activation ensues.
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Thr-821 (Fig. 7C and D). These results provide further support for
the conclusion that in neuroblastoma cells tyrosine phosphor-
ylation negatively regulates the stability and inhibitory activity
of p27KIP1. Moreover, these data demonstrate that inhibition of
p27KIP1 tyrosine phosphorylation exerts growth inhibitory
effects on neuroblastoma cells. Tyr-245 is a major site of
regulatory control in c-Abl. Phosphorylation on Tyr-245, by
disrupting the intra-molecular engagement between the SH3
domain and the SH2-kinase linker domain of the auto-inhibited
structure, stabilizes c-Abl in an open and active conformation
[9]. We found that a significant fraction of cellular c-Abl is
phosphorylated on Tyr-245, consistent with an open and active
conformation of the enzyme. Given the low affinity of phos-
phorylated c-Abl for imatinib (IC50  7 mM) [10,11], this result
provides a molecular explanation for the relatively high imatinib
concentrations (10 mM) required to inhibit neuroblastoma cell
proliferation, reported in this and other studies [13,36]. Impor-
tantly, exposure to imatinib did not affect Tyr-245 phosphory-
lation, suggesting that an imatinib insensitive tyrosine kinase(s)
mediates c-Abl activation in neuroblastoma cells. On the basis of
the well established role played by c-Src in the activation of c-Abl
mitogenic function [37] and the capacity of Src-family kinases to
render c-Abl resistant to imatinib [38], a role for c-Src in c-Abl
activation in neuroblastoma cells can be envisaged. Consistent
with this hypothesis, increased c-Src activity was detected in
neuroblastoma cell lines [39]. Further work is needed to clarify
this issue.
In high risk neuroblastoma, deregulated E2F transcriptional
activity caused by functional inactivation of the tumor suppressor
pRb results in elevated expression of cell-cycle regulatory proteins,
high proliferation rate and aggressive phenotype [40]. Upon
mitogenic stimulation pRb functional inactivation is promoted
through sequential phosphorylation by cyclin D-CDK4/6 and cyclin
E-CDK2 complexes and results in the release of active E2F1-3
transcription factors capable of inducing the expression of genes
encoding proteins crucial for the G1 to S phase transition [41,42]. In
neuroblastoma cells cyclin D1 and CDK4 overexpression has been
reported to play a role in pRb inactivation [30]. In this study, we
show that in imatinib treated cells pRb phosphorylation at the
CDK2-specific Thr-821 and CDK4-specific Ser-780 was decreased
and in parallel the expression of two E2F responsive genes
previously reported to be upregulated in neuroblastoma cells:
SKP2 and cyclin A [30,31] was downregulated. Importantly,
silencing of p27KIP1 prevented the imatinib-dependent down-
regulation of SKP2 and cyclin A whereas expression of p27Y88F/Y89F
recapitulated it. Collectively, these data are consistent with the
conclusion that downregulation of SKP2 and cyclin A is an
important effect of the exposure of neuroblastoma cells to
imatinib. Since SKP2 is reported to act as a cofactor of c-MYC
transcriptional activity [43], it is tempting to speculate that in
imatinib treated cells MYCN transcriptional activity may be
downregulated [31].
The expression by neuroblastoma cells of drug efflux
transporters of the ABC transporter family such as MDR1 [44]
and MRP1 [45] raises the possibility that drug efflux is a major
determinant of the reduced sensitivity of neuroblastoma cells to
imatinib. However, when evaluating this possibility the follow-
ing points should be considered. First, imatinib is not a substrate
for MRP1 [46] which in clinical settings [45] and in animal
models [47] has been demonstrated to be a key factor for
multidrug resistance in neuroblastoma. Second, although ima-
tinib is a substrate of MDR1, the reported IC50 of imatinib for
MDR1 (3–8 mM) [48] is 1–2 log greater than the IC50 of imatinib
for its high affinity targets. Third, while a previous study
demonstrated that MDR1 expression is considerably greater inSK-N-F1 cells than in SK-N-AS cells [49], the inhibition of BrdU
incorporation exerted by imatinib in the two cell lines was
comparable (Fig. 1A). For these reasons and because of the
relatively high imatinib concentration necessary to inhibit active
c-Abl [10,11], a major role for drug efflux transporters in the
resistance of neuroblastoma cells to imatinib shown in this study
seems unlikely. The longer exposure time to imatinib (48 h
instead of 24 h) necessary to inhibit BrdU incorporation in SK-N-
AS cells to an extent comparable with that of the other cell lines
could be explained by the greater amount of Tyr-245 phosphor-
ylated c-Abl detected in these cells (Fig. 8A). However, a reduced
expression or activity of the OCT1 transporter which mediates
imatinib influx [50] could also explain this result.
In conclusion, in this study we demonstrated that in
neuroblastoma cells active c-Abl constitutively phosphorylates
p27KIP1 on tyrosine residues, promoting p27KIP1 downregulation
and uncontrolled cell proliferation (Fig. 12). Moreover, we
provided evidence that the mechanism of the antiproliferative
effect of imatinib on neuroblastoma cells relies on the inhibition of
p27KIP1 tyrosine phosphorylation by active c-Abl. The collaborative
interaction between c-Abl and CDK2 in controlling p27KIP1
stability, suggests a potential synergistic interaction between
imatinib and CDK2 inhibitors in inhibiting neuroblastoma cell
proliferation. Should this be the case, new treatments for the
control of minimal residual disease could be developed. Further
work is needed to test this hypothesis.
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